Development of a collaborative monitoring system between a hospital and community pharmacy using an app for breast cancer outpatients treated with abemaciclib

Development of a collaborative monitoring system between a hospital and community pharmacy using a cancer patient support app for breast cancer outpatients treated with abemaciclib - Development of a collaborative monitoring system between a hospital and community pharmacy using an app

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056331

Enrollment

Registered

2024-12-02

Start date

2022-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient is 20 years of age or older at the time consent is obtained Patients with access to a smartphone Patients who have given written consent to the study

Exclusion criteria

Exclusion criteria: Patients who are unable to use smartphones Patients with brain metastases and associated cognitive dysfunction Patients participating in another clinical study within 28 days prior to enrollment Patients with a performance status of 3 or higher

Design outcomes

Primary

Measure	Time frame
burden, satisfaction, and anxiety associated with app use by patients, pharmacy pharmacists, and physicians(The survey was conducted at two time points: before implementation and in the 6th month after implementation.)	—

Secondary

Measure	Time frame
adverse events, adherence, relative dose intensity (RDI),app input implementation rate, duration of treatment (days) and time to treatment failure (TTF), number of emergency consultations/admissions (times) associated with AEs, interview times at the outpatient pharmacist office (time to check the medication status and symptoms), number of times the pharmacist confirmed the patient's input (the number of times an alert message was confirmed), number of times free messages were added to the diary in the app (from patients to pharmacists and from pharmacists to patients), number of direct calls to the outpatient pharmacist office and the time (minutes) spent on that call.	—

Measure

Time frame

adverse events, adherence, relative dose intensity (RDI),app input implementation rate, duration of treatment (days) and time to treatment failure (TTF), number of emergency consultations/admissions (times) associated with AEs, interview times at the outpatient pharmacist office (time to check the medication status and symptoms), number of times the pharmacist confirmed the patient's input (the number of times an alert message was confirmed), number of times free messages were added to the diary in the app (from patients to pharmacists and from pharmacists to patients), number of direct calls to the outpatient pharmacist office and the time (minutes) spent on that call.

—

Countries

Japan

Contacts

Public ContactMaki Todo

Saitama Medical University Saitama International Medical Center pharmacy

m_todo@saitama-med.ac.jp0429844646

Outcome results